# Plant Health Care plc Q&A with CEO Dr Chris Richards (LON:PHC)

- Link: https://www.directorstalkinterviews.com/plant-health-care-plc-qa-ceo-dr-chris-richards-lonphc/412755107
- Published: 2018-07-19T13:13:35+01:00
- Author: Amilia Stone

**Plant Health Care plc** (LON:PHC) Chief Executive Officer Dr Chris Richards caught
up with DirectorsTalk for an exclusive interview to discuss the performance of their
commercial products, the cash-positive goal, Innatus 3G licencing and the development
of the PREtec peptides.

 

**Q1: Can you tell us how Plant Health Care is performing in regard to its commercial
products?**

**A1**: We’re extremely encouraged with the growths of Harpin αβ which is our main
commercial product. We have been developing that product now, particularly in fruit
and vegetable markets in a number of different countries over the last few years
and we’re now on an established growth track with that.

I’m actually in Mexico as we speak today and it’s fascinating, for export of tomatoes
and peppers, for example, which are grown in the north-west of Mexico for export
to the US, the team there tell me that about a third of that area is now treated
with Harpin αβ which is most encouraging. We see the sales of Harpin αβ in Mexico
have been growing at 20% a year and we anticipate continued growth. In other markets
like Spain, the Pacific Northwest coast of the US, the Cape in South Africa, we 
are established and growing rapidly in those markets and there are more markets 
for us to go at.

So, that’s what’s really driven our 23% compound annual growth rate in Harpin αβ
sales in the last 5 years.

So, we encouraged about that but on top of that, we have two new opportunities which
we’re pursuing. The first of these is Brazilian sugarcane, fruit and vegetables 
I love them I think they’re wonderful but there are 10 million hectares of sugarcane
in Brazil, it’s just a massive crop. Our launch quantity we sold back in the first
quarter of this year, we sold a lunch quantity of $400,000 which, for a company 
who last year sold $7.7 million, that’s really significant. We’ve worked on this
market for the last 3 or 4 years with trials, demonstration trials in the last year
have been even more encouraging than the previous years and led to increases of 
yield of greater than 20% which is an extraordinary reward from a single application
relatively low dose. This helps the sugarcane enormously, especially in times like
now when the sugar price is low, it helps the efficiency of the plants.

We’re also very excited that we’ve got a very strong distributor in Coplacana which
is the largest, very well-established, sugarcane cooperative in Brazil and they 
supply well over half of the agricultural inputs for sugarcane in certainly San 
Paulo where the majority of the cane is. So, they’re very very strong, they’re very
excited about this product so we expect further significant sales this year. If 
you calculate, if we only get 2.5% of those 10 million hectares treated, that would
give us $5 million, it will take us 2/3/4 years to get there but our internal forecasts,
if you can imagine, are significantly higher than that. So, we’re excited about 
Brazilian cane and it’s going really really well.

The second one is we have reached a new agreement in the US that gives us access–
finally, we’ve been seeking this for some time – to the seed treatment market in
corn, in maize and there are 90 million acres of corn in the US and we’ll make our
first sales this year. Unfortunately, I can’t say very much more about because I
can’t pre-empt the launch which will be, we plan, in September this year and we’ll
give more news as we can, but we see very significant potential here. So, our market
expectations are for $10 million of sales in this year and we’re feeling very confident
of meeting that target.

 

**Q2: I think you’ve already alluded to this but how do you think you will achieve
your goal of becoming cash positive and, I guess more importantly, when is it likely
to happen?**

**A2**: This is an absolutely key goal for Plant Health Care. We raised cash earlier
this year and we do not aim to raise more cash, we will, as they say, ‘cut our coats
to suit our cloth’, we will make sure that our cash runway lasts.

We currently have just over $6 million in the bank and our commercial business is
now generating cash and that’s really significant, that will start to release our
cash burn, our cash burn will reduce significantly in 2018 versus 2017 and it will
reduce further in ’19. We will adjust our spending, we are forecasting to spend 
less on R&D than we have done and in other areas as well, administration particularly,
to ensure that we become cash positive whilst maintaining our core capability in
R&D and other areas.

We are very confident of achieving cash positive no later than 2020.

 

**Q3: Is there anything that you can update us with regards to the Innatus 3G licencing?**

**A3**: Yes absolutely. We have some good progress in some areas but a major disappointment
in Brazil.

First, on Brazil, we did trials in the 2016/17 soybean crop in Brazil where we found,
as many other people found, the conventional fungicides were failing to deliver 
good control of Asian Soybean Rust and other disease in soy. That’s a major major
problem for soybean growers in Brazil and indeed the providers of conventional fungicides
and when we did those trails and we added our Innatus 43G peptides to fungicides,
we lifted disease control significantly. That was very very exciting, and we took
those results to the major fungicide companies and they all said, let’s try it and
we’ll see, so on that basis we were confident on getting a licence in the second
half of 2018.

Unfortunately, the 2017/18 trials, conventional fungicides worked really really 
well so frankly, although we did give some benefit in disease management over conventional
fungicides, it was really hard to improve on the conventional fungicides so, frankly,
we were unable to demonstrate that there was an improvement. So, we will try again
next year but it means that, frankly, our partners don’t have any level of conviction
based on the trials from ‘17/18.

However, the good news is that we also had trials in soybean in Brazil which showed
a very promising yield increase of 6%-7% even with low application rates and that’s
a very very valuable proposition for soybean growers. So, we will continue testing
in the next crop, both disease management and the yield management benefits of Innatus
3G peptides but sadly we’re going to need more time before we have good enough data
to be able to seek a licence so sadly, we have had to tell the market that we won’t
get a licence this year.

Outside Brazil however, our partners continue to test both Innatus 3G and our other
peptides on many many crops and in many regions, well over ten crops and we’re getting
some very very interesting results. I have to say that our relationships with our
partners have never been closer, the engagement, the level of interest has never
been better, and we are confident that these will lead a real palpable third-party
endorsement of our technology in relatively short order but frankly, from I sit 
as the CEO and its wary of giving timing on that now, it’s since we failed to deliver
what we said in 2018. I continue to be very optimistic based on the conversations
we’re having with our partners that that third-party endorsement will come.

 

**Q4: With regards to Plant Health Care’s trials on other PREtec peptides, how’s
this developing?**

**A4**: That also continues to go very well, here we’re talking about our nematode
controlled platform, T-Rex and our biostimulant platform Y-Max. Again, our partners
continue to evaluate these platforms and indeed there’s new interest and I’m quietly
confident that we will be adding to our list of partners over the coming months.
Nematodes are little worms in the soil which set back crops very severely in certain
areas and they’re really really hard to control and our peptides are giving good
results.

So, that together with our engagement with partners on Innatus 3G does make me have
a very high level of conviction about the long-term potential of our PREtec Plant
Response Elicitor technology. It’s going to take a little bit more time than we 
anticipated but this technology remains a very very exciting new biological technology
which has the potential to reduce the amount of toxic agri-chemicals that are used
and to benefit farmers around the world.

Share on:
